PTCOG Scientific Program Subcommittee
The PTCOG Scientific Program Subcommittee was authorized at the PTCOG 54 Steering Committee Meeting.
The main charge of the PTCOG Scientific Program Sub- Committee is the organization of the Scientific Meeting of PTCOG Conferences and the management of the selection process of Abstracts for presentation at the Scientific Meeting, both in close collaboration with the local hosts of the Conferences.
The Committee is headed actually by the following Chairpersons:
 |
|
 |
|
 |
|
PTCOG Members are supporting the evaluation and selection process of the Abstracts for the Scientific Meetings. If you are a registered PTCOG Member and interested to join, please contact one of the Chairpersons above.
Please contact one of the Chairpersons for suggestions/contributions to the Scientific Program Subcommittee tasks.
Imaging Subcommittee
Co-Chairs:
This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it.
Charges:
- Survey of imaging equipment
- Site specific IGRT protocols
- Protocol specific information
Bibliography:
- update
Lymphoma Subcommittee
Co-Chairs:
This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it.
Charges:
1) Understand the problems with photon radiation in management with lymphoma
2) Demonstrate the potential benefit of using proton therapy dosimetry to improve upon the limitations of photon radiation listed in Charge 1)
3) Review the current clinical data for using proton therapy in lymphoma and evidence for similarity in disease control
4) Understand which patients are currently receiving proton therapy for lymphoma
5) Share experience regarding how patients are being treated using proton therapy, including treatment planning challenges and developing
best practices.
6) Provide opportunity for collaborative studies among centers evaluating proton therapy in larger combined cohorts
a. Hodgkin lymphoma
b. Non-Hodgkin lymphoma
c. Relapsed/Refractory lymphoma
7) Develop Prospective research: We would like to develop a lymphoma registry combining both proton and photon patients to collect both dosimetric
data and clinical outcomes, in order to identify benefits from proton therapy long term. This registry could be developed in collaboration with ILROG
Bibliography:
PTCOG Lymphoma Subcommittee Work:
Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee.
Tseng YD, Cutter DJ, Plastaras JP, Parikh RR, Cahlon O, Chuong MD, Dedeckova K, Khan MK, Lin SY, McGee LA, Shen EY, Terezakis SA, Badiyan SN, Kirova YM13, Hoppe RT, Mendenhall NP, Pankuch M, Flampouri S, Ricardi U, Hoppe BS.
Int J Radiat Oncol Biol Phys.Int J Radiat Oncol Biol Phys. 2017 Sep 21. Pii: S0360-3016(17)30901 PMID: 28943076
Consolidative Proton Therapy after chemotherapy for patients with Hodgkin lymphoma.
Hoppe BS, Hill-Kayser CE, Tseng YD, Flampouri S, Elmongy HM, Cahlon O, Mendenhall NP, Maity A, McGee LA, Plastaras JP.
Ann OncologyAnn Oncology. 2017 Sep 1;28(9):2179-2184. PMID:28911093
Systematic review for deep inspiration breath hold in proton therapy for mediastinal lymphoma:
A PTCOG Lymphoma Subcommittee report and recommendations
Chirayu G Patel, Jennifer Peterson, Marianne Aznar, Yolanda D Tseng, Scott Lester, Deanna Pafundi, Stella Flampouri, Pranshu Mohindra, Rahul R Parikh, Raymond Mailhot Vega, Laila Konig, John P Plastaras, James E Bates, Pierre Loap, Youlia M Kirova, Ester Orlandi, Carola Lütgendorf-Caucig, Georgios Ntentas, Bradford Hoppe
https://pubmed.ncbi.nlm.nih.gov/36252635/
Risk of Pneumonitis and Outcomes After Mediastinal Proton Therapy for Relapsed/Refractory Lymphoma: A PTCOG and PCG Collaboration
Yolanda D Tseng, Bradford S Hoppe, Katerina Dedeckova, Chirayu G Patel, Christine E Hill-Kayser, David M Miller, Amit Maity, Nancy P Mendenhall, Raymond B Mailhot Vega, Torunn I Yock, Sujith Baliga, Clayton B Hess, Karen M Winkfield, Pranshu Mohindra, Lane R Rosen, Henry Tsai, John Chang, William F Hartsell, John P Plastaras
https://pubmed.ncbi.nlm.nih.gov/32866566/
PBS in Lymphoma:
Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment.
Zeng C, Plastaras JP, James P, Tochner ZA, Hill-Kayser CE, Hahn SM, Both S.
Acta Oncol. 2016 Sep-Oct;55(9-10):1132-1138 PMID27332881
Proton therapy and Breath Hold in Lymphoma:
Comparing Breath Hold and Free Breathing during Intensity-Modulated Radiation Therapy and Proton Therapy in Patients with Mediastinal Hodgkin Lymphoma.
Hoppe BS, Mendenhall NP, Louis D, Li Z, Flampouri S.
Mar 2017, Vol. 3, No. 4 (Spring 2017) pp. 492-496
Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold.
Rechner LA, Maraldo MV, Vogelius IR, Zhu XR, Dabaja BS, Brodin NP, Petersen PM, Specht L, Aznar MC.
Radiother Oncol. 2017 Aug 21. pii: S0167-8140(17)32509-4. doi: 10.1016/j.radonc.2017.07.033. [Epub ahead of print] PMID: 28838605
Proton therapy in Non-Hodgkin lymphoma:
Proton therapy in the management of non-Hodgkin lymphoma.
Sachsman S, Flampouri S, Li Z, Lynch J, Mendenhall NP, Hoppe BS
Leuk Lymphoma. 2015;56(9):2608-12 PMID 25669925
Clinical Trial Results:
Involved-node proton therapy in combined modality therapy in Hodgkin Lymphoma: results of a phase II study.
Hoppe BS, Flampouri S, Zaiden R, Slayton W, Sandler E, Ozdemir S, Dang NH, Lynch JW, Li Z, Morris CG, Mendenhall NP.
Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1053-9. PMID: 24928256
Other:
Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.
Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck af Rosenschöld P, Petersen PM, Specht L.
Ann Oncol. 2013 Aug;24(8):2113-8. PMID: 23619032
Ocular Subcommittee
(The OPTIC Subcommittee was renamed to Ocular Subcommittee in August 2023)
Co-Chairs:
This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it.
Charges:
- To bring professionals of this highly specialized field together and share experience
- To map the status of ocular proton therapy worldwide
- To seek consensus and standardize our clinical procedures
- To address obsoleteness of our facilities on the community level
- To define standards in treatment planning and address discontinuation of Eyeplan
- To develop propose and collaborate in clinical trials
- To collaborate on physics aspects
- Assemble team with names hardest to spell
Recent publication:
Mishra K, Afshar A, Thariat J, Shih H, Scholey J, Daftari I, Kacperek A, Pica A, Hrbacek J, Dendale R, Mazal A, Heufelder J, Char D, Sauerwein W, Weber D, Damato B, Practice considerations for proton beam radiotherapy of uveal melanoma during the COVID-19 pandemic: PTCOG Ocular experience, Advances in Radiation Oncology (2020), DOI: https://doi.org/10.1016/j.adro.2020.04.010
*******
PTCOG Optic Subcommittee Report, June 2022, PTCOG 60, Miami
PTCOG Optic Subcommittee Meeting Report, PTCOG 61, Madrid
Patient Relations Subcommittee
Co-Chairs:
This email address is being protected from spambots. You need JavaScript enabled to view it. , This email address is being protected from spambots. You need JavaScript enabled to view it. , TBD
Charges:
- To create a Peer-Patient Online Community to share real life stories
- To collect information from PTCOG Subcommittees to summarize up-to-date indication information
Bibliography:
- update